Uncategorized

‘Tis the Season

With the cold, the travel and the holidays come a range of illnesses that send people in droves for treatment.  From H1N1 to the good ‘ole sore throat, clinics will continue to see a variety of ailments throughout what promises to be a challenging cold and flu season.  Pharmaceutical dispensing clients of PCA continue to purchase antibiotics, throat lozenges and cold & cough products to provide to their patients.  We are also seeing many orders for medical injectables like Promethazine to alleviate symptoms.

The CDC provides great information for travelers and health professionals as it relates to flu updates, outbreaks and guidance on other health-related information.  Go to www.cdc.gov for more information.  For even more information on the flu, check out www.flu.gov.

As you consider pharma vendors for your medical supplies and pharmaceuticals, consider PCA your partner for the "season".  Bundle up!

Schedule a free claims analysis now.

Let’s Talk now

Leader in AI-driven health benefits navigation Healthee partners with Northwind

Katherine Lurk | Mar 28th, 2025
A game-changer for employers looking to cut costs and gain control With healthcare costs continuing to rise, employers are seeking new ways to rein in spending without sacrificing the quality of benefits. This partnership enables Healthee clients to optimize prescription drug management, reducing costs through preferable generic drug pricing, high-touch chronic care programs, and more. … more »

continue reading

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading